Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Zealand Pharma AS, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Zealand Pharma AS, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Zealand Pharma AS, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Zealand Pharma AS, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Zealand Pharma AS, Medical Devices Deals, 2012 to YTD 2018 10
Zealand Pharma AS, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Zealand Pharma AS, Pharmaceuticals & Healthcare, Deal Details 12
Venture Financing 12
Beta Bionics Raises USD1.5 Million in Series B Financing 12
Partnerships 13
Zealand Pharma and UniQuest Enter into Co-Development Agreement 13
Zealand Pharma Enters into Collaboration Agreement with Beta Bionics 14
Zealand Pharma and Torrey Pines Institute for Molecular Studies Enter into Research Agreement 15
Zealand Pharma and Orbit Discovery Enter into Research Partnership 16
Zealand Pharma Partners with Beta Bionics 17
Zealand Pharma And D. E. Shaw Research Enter Into Research Agreement For Peptide Drug Design 18
Licensing Agreements 19
Zealand Pharma Enters into Licensing Agreement with Boehringer 19
Zealand Pharma Enters Into Licensing Agreement With Abbott Labs For AP214 20
Equity Offering 21
Zealand Pharma Raises USD78.2 Million in Public Offering of American Depositary Shares 21
Zealand Pharma Raises USD21.5 Million in Private Placement of Shares 23
Zealand Pharma Raises USD0.6 Million in Private Placement of Shares upon Exercise of Warrants 24
Zealand Pharma Raises USD0.67 Million in Private Placement of Shares upon Exercise of Warrants 25
Debt Offering 26
Zealand Pharma Raises USD50 Million in Private Placement of Bonds 26
Asset Transactions 27
Royalty Pharma Acquires Royalty Streams and Milestones of Products from Zealand Pharma 27
Zealand Pharma AS – Key Competitors 29
Zealand Pharma AS – Key Employees 30
Zealand Pharma AS – Locations And Subsidiaries 31
Head Office 31
Recent Developments 32
Financial Announcements 32
Aug 16, 2018: Zealand Pharma – Interim report for the first half of 2018 32
May 16, 2018: Zealand Pharma – Interim report for the first quarter of 2018 34
Mar 07, 2018: Zealand Pharma 2017 full-year results in line with guidance – considerable progress in the clinical portfolio 36
Feb 07, 2018: Zealand reports royalty revenue for the fourth quarter of 2017 37
Nov 08, 2017: Zealand Pharma: Interim report for the first nine months of 2017 38
Nov 02, 2017: Zealand reports royalty revenue for the third quarter of 2017 39
Aug 24, 2017: Zealand Pharma: Interim report for the first half of 2017 40
May 17, 2017: Zealand reports results for the first three months of 2017 41
Apr 28, 2017: Zealand reports Q1 2017 royalty revenue 42
Mar 15, 2017: Zealand announces full-year results in line with guidance and releases its Annual Report for 2016 43
Corporate Communications 44
Oct 01, 2018: Zealand Pharma names Marino Garcia as Senior Vice President of corporate business development 44
Jan 19, 2018: Zealand Pharma strengthens its Management by appointing Ivan Møller as SVP, Technical Development & Operations 45
Dec 01, 2017: Employee elected board member change in Zealand Pharma 46
Product News 47
06/12/2017: Zealand to Regain Control of Elsiglutide 47
Product Approvals 48
Oct 24, 2017: U.S. FDA Grants Orphan Drug Designation to Glepaglutide for the Treatment of Short Bowel Syndrome 48
Clinical Trials 49
May 31, 2018: Zealand Pharma to present new clinical Phase 2 results on glepaglutide for the treatment of short bowel syndrome at the DDW conference in the U.S. 49
Apr 26, 2018: Zealand announces successful End-of-Phase 2 meeting with FDA on glepaglutide for short bowel syndrome 50
Jan 23, 2018: New clinical evidence support potential for glepaglutide as a once-weekly drug for short bowel syndrome 51
Jan 23, 2018: Zealand Pharma to present Phase 2 results on glepaglutide at the ASPEN 2018 Conference in Las Vegas, U.S. 52
Dec 07, 2017: Zealand Pharma initiates the pivotal Phase 3 trial with dasiglucagon for the treatment of severe hypoglycemia in diabetes 53
Nov 14, 2017: Recruitment completed in trial to evaluate the optimal dosing frequency for Zealands long-acting GLP-2 analog glepaglutide 54
Oct 12, 2017: Zealand has initiated a clinical trial to evaluate the potential for less than once-daily dosing with its long-acting GLP-2 analog glepaglutide 55
Jul 03, 2017: Zealand initiates first Phase 3 trial with dasiglucagon for the treatment of severe hypoglycemia in diabetes 56
Jun 22, 2017: Phase 2a trial results support development of dasiglucagon in the iLet pump system for type 1 diabetes 57
Jun 19, 2017: Glepaglutide meets primary endpoint in Phase 2 trial in patients with short bowel syndrome 59
Jun 10, 2017: Dasiglucagon (pINN) presentation at the 77th Scientific Sessions of the American Diabetes Association indicate use for treatment of severe hypoglycemia 60
May 23, 2017: Positive Phase 2a results with microdoses of dasiglucagon support use in a dual-hormone artificial pancreas system 61
Feb 06, 2017: Patient recruitment completed for phase II trial with glepaglutide for treatment of short bowel syndrome 62
Other Significant Developments 63
Jul 31, 2018: Zealand announces an 85% increase in Soliqua 100/33/ Suliqua royalty revenue from first to second quarter of 2018 63
Jul 31, 2017: Zealand reports royalty revenue for the second quarter of 2017 64
Appendix 65
Methodology 65
About GlobalData 65
Contact Us 65
Disclaimer 65
Zealand Pharma AS, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Zealand Pharma AS, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Zealand Pharma AS, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Zealand Pharma AS, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Zealand Pharma AS, Deals By Therapy Area, 2012 to YTD 2018 9
Zealand Pharma AS, Medical Devices Deals, 2012 to YTD 2018 10
Zealand Pharma AS, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Beta Bionics Raises USD1.5 Million in Series B Financing 12
Zealand Pharma and UniQuest Enter into Co-Development Agreement 13
Zealand Pharma Enters into Collaboration Agreement with Beta Bionics 14
Zealand Pharma and Torrey Pines Institute for Molecular Studies Enter into Research Agreement 15
Zealand Pharma and Orbit Discovery Enter into Research Partnership 16
Zealand Pharma Partners with Beta Bionics 17
Zealand Pharma And D. E. Shaw Research Enter Into Research Agreement For Peptide Drug Design 18
Zealand Pharma Enters into Licensing Agreement with Boehringer 19
Zealand Pharma Enters Into Licensing Agreement With Abbott Labs For AP214 20
Zealand Pharma Raises USD78.2 Million in Public Offering of American Depositary Shares 21
Zealand Pharma Raises USD21.5 Million in Private Placement of Shares 23
Zealand Pharma Raises USD0.6 Million in Private Placement of Shares upon Exercise of Warrants 24
Zealand Pharma Raises USD0.67 Million in Private Placement of Shares upon Exercise of Warrants 25
Zealand Pharma Raises USD50 Million in Private Placement of Bonds 26
Royalty Pharma Acquires Royalty Streams and Milestones of Products from Zealand Pharma 27
Zealand Pharma AS, Key Competitors 29
Zealand Pharma AS, Key Employees 30
List of Figures
Zealand Pharma AS, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Zealand Pharma AS, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Zealand Pharma AS, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Zealand Pharma AS, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Zealand Pharma AS, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Zealand Pharma AS, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Zealand Pharma AS, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Zealand Pharma AS, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Zealand Pharma AS, Medical Devices Deals, 2012 to YTD 2018 10
